Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 5,000 Shares of Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 5,000 shares of Tonix Pharmaceuticals stock in a transaction that occurred on Wednesday, November 11th. The stock was acquired at an average price of $4.05 per share, for a total transaction of $20,250.00. Following the transaction, the chief executive officer directly owned 16,005 shares of the company’s stock, valued at $64,820.25. The trade was a 45.43% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Seth Lederman also recently made the following trade(s):

• On Thursday, August 27th, Seth Lederman purchased 2,000 shares of Tonix Pharmaceuticals stock. The shares were acquired at an average cost of $13.79 per share, for a total transaction of $27,580.00.

Tonix Pharmaceuticals Stock Down 16.3%

Tonix Pharmaceuticals stock opened at $3.24 on Friday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $3.21 and a 52-week high of $20.56. The firm’s fifty day moving average is $7.93 and its 200 day moving average is $11.92. The company has a market cap of $62.95 million, a price-to-earnings ratio of -0.26 and a beta of 1.90.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, November 9th. The company reported ($2.89) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.50). Tonix Pharmaceuticals had a negative return on equity of 80.97% and a negative net margin of 420.45%. The business had revenue of $17.23 million during the quarter, compared to analysts’ expectations of $16.32 million. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -10.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

TNXP has been the subject of several recent research reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, October 20th. Canaccord Genuity Group assumed coverage on Tonix Pharmaceuticals in a research report on Monday, October 26th. They set a “buy” rating and a $18.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Finally, Wall Street Zen raised Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, October 4th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $22.33.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Large investors have recently made changes to their positions in the company. Global Retirement Partners LLC bought a new position in Tonix Pharmaceuticals during the 3rd quarter valued at about $28,000. Integrated Wealth Concepts LLC bought a new stake in Tonix Pharmaceuticals in the second quarter worth about $92,000. Great Lakes Advisors LLC purchased a new position in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $303,000. Bank of New York Mellon Corp boosted its position in shares of Tonix Pharmaceuticals by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 30,426 shares of the company’s stock valued at $418,000 after buying an additional 6,362 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Tonix Pharmaceuticals by 101.1% during the first quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock valued at $838,000 after buying an additional 30,644 shares during the period. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.